公开(公告)号：US20230210141A1

公开(公告)日：2023-07-06

申请号：US17803480

申请日：2022-07-28

申请人： Edward T. Wei

发明人： Edward T. Wei

IPC分类号： A23L2/56 ,  A23L2/60 ,  A23F5/48

CPC分类号： A23L2/56 ,  A23L2/60 ,  A23F5/483

摘要： A beverage is a drinkable liquid. Described here is a beverage containing a cooling agent that will exert cooling sensations in the upper center of the chest and make a subject feel comfortable. The cooling agent is an agent that targets TRPM8 receptors on nerve cell membranes. The beverage can be imbibed without unpleasant taste and the goal is to make the whole body feel cooler for about 20 min or more after drinking. By choosing the right molecule and right concentration, cooling intensity, location, and duration in the chest is controlled. Surprisingly, the cooling agent was also effective when consumed with warm or hot beverages. The beverage contains selected 1-diisopropyl-phosphinoyl-alkanes and taste-modulating agents selected from sweeteners, extracts from hops, ginger, or cinchona. Various uses of this cooling beverage are proposed.

公开(公告)号：US20220265687A1

公开(公告)日：2022-08-25

申请号：US17803311

申请日：2022-05-03

申请人： Edward T. Wei

发明人： Edward T. Wei

IPC分类号： A61K31/662 ,  A61K9/00 ,  A61P17/04

摘要： The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of the discomforts of dermatological disorders (e.g., diseases) The treatment is for the dysesthesia (e.g., caused by irritation, itch, or pain) due to dermatitis, urticaria; scalp itch; vulvar itch; lichen sclerosus; cholestatic itch; psoriasis; sebhorrheic dermatitis; allergic conjunctivitis; blepharitis; and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates the dysesthesia of these conditions in human subjects. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in the treatment of the dysesthesia of these dermatological disorders.

公开(公告)号：US20210153773A1

公开(公告)日：2021-05-27

申请号：US16854641

申请日：2020-04-21

申请人： Edward T. Wei ,  Bin Sun ,  Zhengrong Tang

发明人： Edward T. Wei ,  Bin Sun ,  Zhengrong Tang

IPC分类号： A61B5/08 ,  A61B5/00 ,  A61B7/00 ,  A61B5/01 ,  A61K31/194

摘要： Cough is a common experience and the most frequent reason why an individual seeks a visit to a physician. The prevalence of cough is about 10+% of the population. Cough is a manifestation of many aerodigestive tract disorders and especially consequential for serious lower airway diseases such as respiratory infections, chronic obstructive pulmonary disease (COPD) and asthma because increased coughing leads to emergency room visits and hospitalization. There is a need for methods to oversee coughing frequency in certain patients. Traditionally, all automated cough monitors have used cough sound as the signal for the measurement of cough. In the present invention movements of the diaphragm muscle, recorded by a motion sensor placed above the xiphoid process, are used for counting coughs. A device for such recordings is described and data were collected. This method is validated by using citric acid spray to trigger cough sounds and to show that the provoked acoustic signal is matched by the electronic signals from the movement sensors. The xiphoid process is a unique anatomical landmark for the non-acoustic detection of cough.